SCHEMBL3462968

SCHEMBL3462968

CC(C)(C)N1CCCC1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.49
LMNA P02545 2/20 0.49
CYP2C19 P33261 1/20 0.49
ACE P12821 9/20 0.41
REN P00797 3/20 0.41
KDM4E B2RXH2 1/20 0.41
F2 P00734 1/20 0.41
LTA4H P09960 1/20 0.41
MAPT P10636 1/20 0.41
PEPD P12955 1/20 0.41
ALOX15 P16050 1/20 0.41
PTGS1 P23219 1/20 0.41
HTR2A P28223 1/20 0.41
PTGS2 P35354 1/20 0.41
HRH1 P35367 1/20 0.41
THPO P40225 1/20 0.41
PMP22 Q01453 1/20 0.41
ACE2 Q9BYF1 1/20 0.41
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1905956 1.00 HSD17B10 (0.49) HSD17B10LMNACYP2C19ACEREN
SCHEMBL10037292 1.00 HSD17B10 (0.49) HSD17B10LMNACYP2C19ACEREN
Hydrochloric Acid SCHEMBL17459605 0.98 HSD17B10 (0.47) HSD17B10LMNACYP2C19ACEREN
Hydrochloric Acid SCHEMBL11222735 0.98 HSD17B10 (0.47) HSD17B10LMNACYP2C19ACEREN
SCHEMBL5429806 0.94 LMNA (0.44) HSD17B10LMNACYP2C19ACEREN
SCHEMBL10037291 0.94 LMNA (0.44) HSD17B10LMNACYP2C19ACEREN
SCHEMBL1592788 0.94 LMNA (0.44) HSD17B10LMNACYP2C19ACEREN
SCHEMBL5702246 0.87 LMNA (0.40) HSD17B10LMNACYP2C19ACEREN
SCHEMBL5702250 0.87 LMNA (0.40) HSD17B10LMNACYP2C19ACEREN
SCHEMBL12312731 0.87 LMNA (0.40) HSD17B10LMNACYP2C19ACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0636140-B1 PARTIALLY MODIFIED AND RETRO-INVERTED TETRAPEPTIDES ANALOGUES OF C-REACTIVE PROTEIN FRAGMENTS ITALFARMACO SPA (IT) 1997-09-10 EP claimed
CN-119707995-A Preparation method of natural alkaloid (+) -RHYNCHINE E compound 郑州大学 2025-03-28 CN disclosed
CN-119470406-A Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof 山东新华莎罗雅生物技术有限公司 2025-02-18 CN disclosed
CN-119012914-A Method for controlling parasitic plants 味之素株式会社 2024-11-22 CN disclosed
US-20240207353-A1 USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-06-27 US disclosed
US-20240207353-A1 USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-06-27 US disclosed
CN-115066423-B PD-L1 antagonist compounds 厦门宝太生物科技股份有限公司 2024-02-02 CN disclosed
US-11760761-B2 Methods and compositions for targeting PD-L1 ALIGOS THERAPEUTICS, INC. (US) 2023-09-19 US disclosed
US-20220153729-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-05-19 US disclosed
US-20220041583-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OF BETTA PHARMACEUTICALS CO., LTD (CN) 2022-02-10 US disclosed
US-20080009524-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2008-01-10 US disclosed
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2007-11-15 US disclosed
US-7109343-B2 Metal catalysts and methods for making and using same THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2006-09-19 US disclosed
US-20050010049-A1 Metal catalysts and methods for making and using same DAVIES HUW M L (US) 2005-01-13 US disclosed
US-6762304-B2 BIS-TRANSITION METAL CATALYSTS HAVING D2 SYMMETRY RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2004-07-13 US disclosed
EP-1173278-B1 METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME RES FOUNDATION OFSTATE UNIVERS (US) 2004-06-30 EP disclosed
US-20020183535-A1 Metal catalysts and methods for making and using same DAVIES HUW M L (US) 2002-12-05 US disclosed
US-6410746-B1 ORGANOMETALLIC COMPOUND CONTAINING TRANSITION METAL RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE 2002-06-25 US disclosed
EP-0010347-B1 NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION AMERICAN CYANAMID COMPANY (US) 1983-11-09 EP disclosed
EP-0010347-A1 Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation AMERICAN CYANAMID COMPANY (US) 1980-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity FABP4, GPR119, PGC HSD17B10 331/4885LMNA 374/4885CYP2C19 516/4885
US-20020183535-A1 Metal catalysts and methods for making and using same COMT, SLC6A3, SLC6A2 HSD17B10 1968/4885LMNA 2546/4885CYP2C19 71/4885
US-20220041583-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OF IL2, TSLP, CD74 HSD17B10 2663/4885LMNA 4672/4885CYP2C19 2965/4885
US-20080009524-A1 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 HSD17B10 1734/4885LMNA 3455/4885CYP2C19 1915/4885
US-11760761-B2 Methods and compositions for targeting PD-L1 CD274, PDCD1LG2, PDCD1 HSD17B10 712/4885LMNA 2102/4885CYP2C19 3260/4885
US-20220153729-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 HSD17B10 1620/4885LMNA 3535/4885CYP2C19 1649/4885
US-20050010049-A1 Metal catalysts and methods for making and using same SLC6A3, COMT, DRD4 HSD17B10 1952/4885LMNA 2606/4885CYP2C19 59/4885
US-20240207353-A1 USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS VIP, GRPR, ITCH HSD17B10 2279/4885LMNA 4688/4885CYP2C19 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.